Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Nephrol. Jun 25, 2026; 15(2): 118877
Published online Jun 25, 2026. doi: 10.5527/wjn.v15.i2.118877
Published online Jun 25, 2026. doi: 10.5527/wjn.v15.i2.118877
Is the metabolic dysfunction-associated steatotic liver disease a predictor of chronic kidney disease?
Nashwa M Azoz, Essam M Abdel Aziz, Department of Internal Medicine-Nephrology Unit, Assiut University Hospital, Faculty of Medicine, Assiut University, Assiut 71711, Egypt
Marwa A Shehata, Department of Internal Medicine-Endocrinology Unit, Assiut University Hospital, Faculty of Medicine, Assiut University, Assiut 71711, Egypt
Wael A Abbas, Department of Internal Medicine-Gastroenterology Unit, Faculty of Medicine, Assuit University, Assuit 71511, Egypt
Rabea A Gadelkareem, Department of Urology, Assiut Urology and Nephrology Hospital, Faculty of Medicine, Assiut University, Assiut 71515, Egypt
Author contributions: Azoz NM and Shehata MA designed the research, collected the data, and wrote the paper; Gadelkareem RA and Abdel Aziz EM contributed to the statistical analysis, literature review, writing, and revision; and Abbas WA contributed to the literature review, writing, revision, and supervision of the work. All authors have approved the manuscript.
Institutional review board statement: The proposal of this study was approved by the Ethics Committee of the Faculty of Medicine, Assiut University, Egypt, on November 9, 2023. The institutional review board number is No. 04-2023-200487.
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STORBE Statement, and the manuscript was prepared and revised according to the STORBE Statement.
Data sharing statement:
The raw data will be available from the authors on reasonable request.
Corresponding author: Rabea A Gadelkareem, MD, Assistant Professor, Department of Uro
Received: January 13, 2026
Revised: January 30, 2026
Accepted: March 2, 2026
Published online: June 25, 2026
Processing time: 153 Days and 15.9 Hours
Revised: January 30, 2026
Accepted: March 2, 2026
Published online: June 25, 2026
Processing time: 153 Days and 15.9 Hours
Core Tip
Core Tip: Metabolic dysfunction-associated steatotic liver disease (MASLD) is now recognized as a multisystem disease. It is closely linked to obesity, insulin resistance, type-2 diabetes mellitus (DM), dyslipidemia, and hypertension. The present case-control study revealed that MASLD is strongly associated with chronic kidney disease, particularly in patients with DM and advanced hepatic fibrosis. The factors associated with chronic kidney disease included hepatic fibrosis score, steatosis score, Homeostasis Model Assessment of Insulin Resistance, DM, and obesity. Incorporating liver fibrosis assessment using FibroScan may aid in the early identification of patients with MASLD who are at high risk for renal disease.